Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P21731

UPID:
TA2R_HUMAN

ALTERNATIVE NAMES:
Prostanoid TP receptor

ALTERNATIVE UPACC:
P21731; O75228; Q6DK52; Q9UCY1; Q9UCY2

BACKGROUND:
Thromboxane A2 receptor, known for its alternative name Prostanoid TP receptor, is integral in mediating platelet aggregation and vasoconstriction. It activates phospholipase C and adenylyl cyclase, playing a dual role in cellular signaling pathways. This receptor's activity is essential for normal blood clotting and kidney function.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Thromboxane A2 receptor could open doors to potential therapeutic strategies for bleeding disorders. Its direct involvement in Bleeding disorder, platelet-type, 13, highlights its significance in developing targeted therapies to regulate platelet function and prevent excessive bleeding.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.